Systematic literature review of efficacy and safety of first-line maintenance therapy trials in advanced ovarian cancer
Aim: To review safety and efficacy outcomes in studies of first-line maintenance therapies for advanced ovarian cancer. Methods: A systematic literature review was performed (27 February 2020) to identify clinical outcomes including progression-free survival (PFS), overall survival (OS) and Grade ≥3 adverse events. Results: Overall 50 references met prespecified criteria; 18 studies evaluated 10 different agents, including PARP inhibitors. PFS was an end point in 16 trials and OS in 12 trials. PARP inhibitors reported better PFS hazard ratios (HRs: 0.59-0.68) compared with other classes; no mature OS data were identified. Safety reporting was inconsistent. Conclusion: Reported PFS HRs were better for PARP inhibitors than for other ovarian cancer maintenance therapies; overall survival data remain immature.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Future oncology (London, England) - 18(2022), 30 vom: 20. Sept., Seite 3435-3447 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Guy, Holly [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.11.2022 Date Revised 04.11.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/fon-2022-0578 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346190479 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346190479 | ||
| 003 | DE-627 | ||
| 005 | 20231226030828.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/fon-2022-0578 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1153.xml |
| 035 | |a (DE-627)NLM346190479 | ||
| 035 | |a (NLM)36102225 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Guy, Holly |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Systematic literature review of efficacy and safety of first-line maintenance therapy trials in advanced ovarian cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.11.2022 | ||
| 500 | |a Date Revised 04.11.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: To review safety and efficacy outcomes in studies of first-line maintenance therapies for advanced ovarian cancer. Methods: A systematic literature review was performed (27 February 2020) to identify clinical outcomes including progression-free survival (PFS), overall survival (OS) and Grade ≥3 adverse events. Results: Overall 50 references met prespecified criteria; 18 studies evaluated 10 different agents, including PARP inhibitors. PFS was an end point in 16 trials and OS in 12 trials. PARP inhibitors reported better PFS hazard ratios (HRs: 0.59-0.68) compared with other classes; no mature OS data were identified. Safety reporting was inconsistent. Conclusion: Reported PFS HRs were better for PARP inhibitors than for other ovarian cancer maintenance therapies; overall survival data remain immature | ||
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a BRCA mutation | |
| 650 | 4 | |a PARP inhibitor | |
| 650 | 4 | |a first-line maintenance | |
| 650 | 4 | |a ovarian cancer | |
| 650 | 4 | |a progression-free survival | |
| 650 | 4 | |a systematic literature review | |
| 650 | 7 | |a Poly(ADP-ribose) Polymerase Inhibitors |2 NLM | |
| 700 | 1 | |a Hawkes, Carol |e verfasserin |4 aut | |
| 700 | 1 | |a Walder, Lydia |e verfasserin |4 aut | |
| 700 | 1 | |a Malinowska, Izabela A |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Divya |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future oncology (London, England) |d 2005 |g 18(2022), 30 vom: 20. Sept., Seite 3435-3447 |w (DE-627)NLM161450725 |x 1744-8301 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2022 |g number:30 |g day:20 |g month:09 |g pages:3435-3447 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/fon-2022-0578 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2022 |e 30 |b 20 |c 09 |h 3435-3447 | ||